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Background: In order to ensure an adequate and ongoing protection of individuals participating in scientific
research, the impacts of new biomedical technologies, such as Next Generation Sequencing (NGS), need to be
assessed. In this light, a necessary reexamination of the ethical and legal structures framing research could lead to
requisite changes in informed consent modalities. This would have implications for Institutional Review Boards
(IRBs), who bear the responsibility of guaranteeing that participants are verifiably informed, and in sufficient detail,
to understand the reality of genetic research as it is practiced now. Current literature allowed the identification of
key emergent themes related to the consent process when NGS was used in a research setting.
Methods: We examined the subjects of secondary use, sharing of materials and data, and recontacting participants
as outlined in the Canadian Informed Consent templates and the accompanying IRB instructions for the conduct of
genetic research. The research ethics policy applied by the three Canadian research agencies (Tri-Council Policy
Statement, 2nd Edition) was used to frame our content analysis. We also obtained IRB-approved consent forms for
genetic research projects on brain and mental health disorders as an example of a setting where participants might
present higher-than-average vulnerability.
Results: Eighty percent of documents addressed different modalities for the secondary use of material and/or data,
although the message was not conveyed in a systematic way. Information on the sharing of genetic sequencing
data in a manner completely independent of the material from which it originated was absent. Grounds for
recontacting participants were limited, and mainly mentioned to obtain consent for secondary use. A feature of the
IRB-approved consent documents for genetic studies on brain and mental health disorders using NGS technologies,
offered a complete explanation on sharing material and data and the use of databases.
Conclusions: The results of our work show that in Canada, many NGS research needs are already dealt with. Our
analysis led us to propose the addition of well-defined categories for future use, adding options on the sharing of
genetic data, and widening the grounds on which research participants could consent to be recontacted.
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There is a constant need to fine-tune the balance between
the potential of new biomedical advances and the ethical
and legal structures needed to ensure the protection of
human subjects involved in research projects [1]. It is be-
coming clear that identical consent modalities cannot ac-
commodate all scenarios. For instance, recent reports
propose reforming the ethical oversight for low-risk ran-
domized research projects, using an abridged consent
process, where participants are not required to sign con-
sent forms [2]. In the case of genomic studies, the advent
of Next Generation Sequencing (NGS) is changing the
previously established balance in the consent process
[3-5]. As a result, there is an ongoing discussion about
how new IC models and approaches should evolve, with a
view to conveying necessary information while buttressing
the autonomy of participant decisions [6,7]. Proposed new
models involve the use of parceled out IC for result dis-
closure, implying an active collaboration between ethics
boards, researchers and participants so as to provide op-
tions for returning results according to immediate action-
ability, reproductive significance and personal utility [6].
Another example is the “Informed Cohort” model in
which there is continuous interaction between researchers
and participants when providing and receiving genetic re-
sults, entailing the active use of educational tools [7].
These changes impel Institutional Review Boards (IRBs) to
adapt their ethical reviews to a new language and entertain
novel concepts in order to better safeguard research partic-
ipants’ rights without hindering expected scientific ad-
vancements. Therefore, IRBs may need to see if their
current recommendations to researchers, offered in the
form of templates and guiding documents, are apt to offer
research participants information that truly reflect the state
of genetics research as well as the paths it may yet follow.
Previous analysis on the use of NGS in research and the
ethical and social issues surrounding participant protec-
tion allowed the identification of several key, emergent
themes related to the consent process [8,9]. Important as-
pects include the assurance of understanding, by partici-
pants, of both the science underlying the protocol and the
complex possible outcomes of current genetic research;
adequate provision of genetic counseling; confidentiality;
specifications of secondary use and sharing of material
and data, and the various reasons for frequent contact be-
tween researchers and participants, among others. In this
manuscript, we discuss the subjects of secondary use (also
referred to as future use), sharing of material and data in
relation to secondary use, and recontacting participants.
These three subjects are interconnected and have in
common that in order to be implemented, they require
anticipation by, and coordination between, IRBs and re-
searchers; they could be viewed as vague concepts by
participants, which makes them harder to explain; andthey are directly linked to the principle of respecting priv-
acy. The goal of this study was to determine if current
Canadian IC templates and accompanying IRB instruc-
tions are consistent with the ethical challenges posed by
the rise of NGS technologies in the aforementioned con-
texts. We used the research ethics policy applied by the
three Canadian research agencies (Tri-Council Policy
Statement 2nd Edition, hereafter TCPS2) [10] to frame our
content analysis. Institutions that receive and administer
research funds from these agencies must comply with the
TCPS2. Finally, based on earlier research [8,9,11] indicat-
ing that research participants with brain and mental
health disorders might present higher-than-average vul-
nerability, we examined IRB-approved consent forms for
NGS research protocols targeting this population.
Materials
Sample collection
In order to evaluate if Canadian IC templates and accom-
panying IRB instructions address the current challenges of
secondary use, sharing and recontacting participants in
the framework of genetic research, the collection process
consisted of selecting consent templates and guidelines
pertaining to genetic/genomic studies. We also included
documents produced for the banking of biological mate-
rials in the context of a genetic/genomic research project.
We collected publicly available consent form templates
from Canadian IRBs, various websites (universities, hospi-
tals, research institutes), or by requesting templates from
members of the Canadian Association of Research Ethics
Boards (CAREB) or IRB personnel, when their contact in-
formation was publicly available. We sought to achieve
the widest possible Canadian geographical representation.
In the course of our study, we obtained IRB-approved
consent forms for different NGS research projects study-
ing mental health and brain disorders currently conducted
at Canadian institutions.
Sample documents were collected between January
and September 2012. At the end of this period, all infor-
mation was rechecked for currency. Documents that had
been modified since the initial collection were updated
until the assembly of material was considered complete.
We gathered a total of 60 documents. Thirteen out of
the 60 documents were excluded either because of dupli-
cation or because they were unrelated to our goals. Our
final sample consisted of 47 documents. In addition, we
obtained six IRB-approved consent forms for genetic pro-




We chose to work with templates because we considered
them accessible tools used to build the consent forms
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guidelines or policies. The arrangement of documents was
not uniform among IRBs, as the following variants partly
attest to: ‘Consent Form for Genetic Research’, ‘Primary
Consent Form’ with a separate ‘Addendum for Genetic
Studies’. Given this divergence, we organized the docu-
ments as units of analysis (UAs), in the same way as the
IRBs indicated they should be used by researchers. Units
of analysis were comprised of individual forms (e.g., con-
sent form template) or a combination of forms (e.g.,
primary consent template with additional secondary
template for genetic research), much as they would be
presented to a potential research participant. If an IRB
produced one consent template for genetics research
with adult participants and a different one for children,
we analyzed them as two separate units of analysis: one
for adult genetics and another for pediatric genetics.
This distinction was drawn to capture possible differ-
ences characterizing each population. UAs were classi-
fied according to the scope of research, i.e., Cancer
Genetics; Pediatric Genetics; Genetics; Pharmacogen-
omics, etc. (Table 1a).
Following an early stage of examining the material, we
determined that the themes of our analysis were not al-
ways present in all documents. Thereafter we searched
for other texts issued by each corresponding institution
so that their approach to the issues dealt with in this
manuscript was reflected as completely as possible. In
other words, before stating that a subject was not dealt
with by an IRB, we made sure that it was not present in
any of the material produced by that body. Thus, UAs
were composed of one or more consent form templates
(depending on, for instance, whether an IRB worked
with a single consent form for genetic studies or a gen-
eral consent form and a secondary, optional one, for
genetic studies), whereas in some cases, UAs were com-
posed of a template(s) and an additional document (i.e.,
guidelines).
We examined a total of 37 UAs that resulted from
combining 47 different template documents without dis-
closing the institutions from which those were obtained.
Due to their limited number, IRB-approved consent
forms for studies involving the genetics of brain or men-
tal health disorders were analyzed as a distinct group, so
as to avoid any possible identification of the researchers
involved, and also because they did not lend themselves
as well to comparison.
Data analysis process
We applied content analysis to the UAs as previously de-
scribed [12,13]. Content analysis is a general term for a
number of different strategies used to analyze texts. It
seeks to describe the characteristics of a document’s
content by examining, for instance, what is being said, towhom, and to what effect. It allows for both quantitative
and qualitative analysis of data [14,15].
Each document was first read so as to identify key
themes and then read again and coded to obtain the
sense of the whole and to identify additional key themes.
Finally, all key themes were subdivided into any sub-
themes that could emerge. This analysis was informed
by issues linked to the consent process in the context of
NGS technologies (i.e., whole genome sequencing, ex-
ome sequencing), issues that were brought to the fore in
recent analyses [8,9]. We evaluated the current ethical
issues in need of deeper analysis in light of the application
of the newest genomic technologies in research and the
ensuing implications for individuals and social groups.
The reliability and validity of the findings were
strengthened by having two individuals with different
fields of expertise (IJG, molecular biology; NE, bioethics)
analyzing the IC documents separately to code them. The
next stage of data analysis consisted of open coding, col-
lecting codes under potential themes and subthemes,
comparing the emerging coding clusters together and in
relation to the entire data set. The final stage of data ana-
lysis consisted of reporting the results of the previous
stages using different categories, as an expression of the
manifest content of our UAs. In this article we present the
categories of future use, recontact of participants and data
sharing in relation to future use because of the way they
were linked in terms of implementation and the provision
of informed consent. An independent content analysis on
the themes of “Genetic Counseling”, “Return of results”,
and “IRB-Approved forms for NGS research in mental
health” was previously reported [12].Identification of targeted subjects and TCPS2 coverage
The research ethics policy applied by the three Canadian
research agencies (TCPS2 [10]) was used to frame our
content analysis. The subject of future or secondary use
of biological material and/or data is discussed exten-
sively throughout the TCPS2 [10], underlining the fact
that it is a recurring issue at different stages of the eth-
ical conduct of a research project. It is addressed in the
contexts both of research and of the collection of bio-
logical materials (including genetic material), as well as
for general or particularly vulnerable populations.Results
Characteristics of IC documents
We evaluated if and how secondary use was presented
in our UAs. Out of a total of 37 UAs, 33 broached this
subject (Table 1a). One in 33 addressed secondary use
(Table 1a), but outside the context of genetics. We
therefore analyzed 32 secondary-use UAs, classified ac-
cording to the field of research (Table 1a). The field was
Table 1 Classification of units of analysis (UAs), headings addressing and options for secondary use
a: Secondary use: classification of units of analysis (UAs) Document Total
Primary Primary plus addendum
No Scope of research Generic 1 1
Genetics 2 2
Tissue Genetics 1 1
Total 4 4
Yes Scope of research Cancer Genetics 1 2 3
Cardiovascular Genetics 1 0 1
Clinical Genomics 1 0 1
Generic 1 0 1
Genetics 12 7 19
Mental Health Genetics 2 1 3
Pediatric Genetics 2 2 4
Tissue Genetics – Future 0 1 1
Total 20 13 33
Total Scope of research Cancer Genetics 1 2 3
Cardiovascular Genetics 1 0 1
Clinical Genomics 1 0 1
Generic 2 0 2
Genetics 14 7 21
Mental Health Genetics 2 1 3
Pediatric Genetics 2 2 4
Tissue Genetics 1 0 1
Tissue Genetics – Future 0 1 1
Total 24 13 37
b: Headings Frequency Percent Valid percent Cumulative percent
Valid Banking 1 2.7 2.7 2.7
Banking for future research 1 2.7 2.7 5.4
Biobanking for future research, consent 1 2.7 2.7 8.1
Biobanking for future research, use of samples and
data, consent
1 2.7 2.7 10.8
Biobanking for future research, use of samples,
consent, access to samples, risk
1 2.7 2.7 13.5
2 5.4 5.4 18.9
Consent 2 5.4 5.4 24.3
Consent, subject care 1 2.7 2.7 27.0
Description of research, consent 1 2.7 2.7 29.7
Description of research, consent, use of samples 1 2.7 2.7 32.4
Description of the research, consent, future research 1 2.7 2.7 35.1
Future contact/future research/other use 1 2.7 2.7 37.8
Future use, biological specimens 1 2.7 2.7 40.5
Introduction, optional studies 1 2.7 2.7 43.2
Invitation to participate 1 2.7 2.7 45.9
Main title, introduction, consent 1 2.7 2.7 48.6
Not applicable 5 13.5 13.5 62.2
No heading 1 2.7 2.7 64.9
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Table 1 Classification of units of analysis (UAs), headings addressing and options for secondary use (Continued)
Optional studies, confidentiality 1 2.7 2.7 67.6
Options to participants 2 5.4 5.4 73.0
Other research 2 5.4 5.4 78.4
Other Research, consent 1 2.7 2.7 81.1
Procedures 1 2.7 2.7 83.8
Purpose of study, study procedures 1 2.7 2.7 86.5
Sample collection, project description, consent 1 2.7 2.7 89.2
Secondary use 1 2.7 2.7 91.9
Use of samples 1 2.7 2.7 94.6
Withdraw 2 5.4 5.4 100.0
Total 37 100.0 100.0
c: Options for secondary use Frequency Percent Valid percent Cumulative percent
Valid Determined by consenting to participate in the study 5 13.5 13.5 13.5
NA 5 13.5 13.5 27.0
No future use plus other options 8 21.6 21.6 48.6
Other research 1 2.7 2.7 51.4
Various options 18 48.6 48.6 100.0
Total 37 100.0 100.0
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the institution.
Secondary use
Secondary use (also called “future use” in TCPS2 [10]
and in several documents analyzed herein) was men-
tioned in documents’ main title, main title and subtitles,
or in no title at all. In addition it was present in a variety
of categories ranging from optional studies to confiden-
tiality and storage of samples, among others (Table 1b).
In our UAs, IRBs suggested different approaches to
obtain participant consent for secondary use of their
samples or data. Twenty seven UAs (27/32) provided
template texts. For 22 of those 27 we also found instruc-
tions to researchers on how to approach the issue of sec-
ondary use at time of consent. The 5 out of 32 UAs
without template texts had instructions to researchers
included in IRB documents other than templates.
We found various modalities for secondary use. Partic-
ipants either had no choice presented, or could choose
among a varying number of options on secondary use,
for instance that samples will be destroyed, or samples
will be banked. Only eight UAs (8/32) provided a clear
choice of no secondary use (future use) at all (Table 1c).
Four UAs (4/32) foresaw the use of collected samples
for future research in deceased participants, in accord-
ance with the reference on local regulations (Art 12.1,
TCPS2) [10].
The following were present as general information
(not options) to participants: the possible use of second-
ary data from linked databases (2/32), while three in 32explained that because of the fast changes in technology
“the potential future use of genetic information is un-
known” and so potential future risks derived from such
information were also unknown. One UA (1/32) advised
researchers that when there were plans to use “genetic
testing…to determine eligibility”, that had to be men-
tioned when discussing secondary use.
According to guidelines set forth in the TCPS2 [10],
any plans on secondary use of identifiable data or mate-
rials need to be approved by the institutional IRB. We
thus checked if our UAs contained any message to be
conveyed to participants in this regard, or, alternatively,
a reminder to researchers about this requirement. A
total of 18 UAs (18/32) presented a text on this subject.
As for the object of secondary use, 19 UAs referred to
biological material only (19/32). Secondary use of data
only was described in 2 (2/32), while secondary use of
both material and data was described in 10 (10/32). One
UA (1/32) did not describe the goal of secondary use.Sharing data and material related to future use
The TCPS2 [10] requests that researchers provide partic-
ipants with “a description of the anticipated uses of data”
(art 3.2), to help them make an “informed decision” on
whether to participate or not in a given research project.
In addition, it requests that IRBs receive an explanation
of “the full life cycle” of collected information (art 5.3).
For “genetic material banks” (art 13.7a), researchers are
asked to specify to participants and IRBs the “use of the
data and results” as well as the “ethical issues” raised
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(Art 13.7b).
A total of 26 out of 37 UAs discussed the matter of
“sharing” (Table 2a). Two of these 26 UAs are included
in this group because the subject of sharing was dis-
cussed in additional documents, although not in the
templates. We analyzed how “sharing” is framed in the
UAs to recognize how it might be conveyed to partici-
pants. Sharing of data and material was addressed under
different headings varying from confidentiality to genetic
testing/genetic research, other research or mentioned in
the IC template text without any title drawing attention
to it.
We explored sharing materials and data in relation to
secondary (future) use (Table 2a), and if data and mate-
rials were considered two separate entities (Table 2b).
We found that the matter of “sharing” (material and/or
data) was either presented in relation to secondary use
(19/26), not definitely related to secondary use (2/26),
or, still, not related to secondary use (5/26) (Table 2a). A
total of 15 UAs (15/26) discuss the sharing of material
independently of sharing data, while the rest mentioned
sharing material only (7/26) or sharing material and dataTable 2 Sharing of material and data
a: Sharing of material and data In relation to secondar
NA
Sharing material and/or data No 10
Yes 0
Total 10





c: REB in sharing material/data REB mentioned
NA
Sharing material and/or data No 11
Yes 0
Total 11
d: Particularities on sharing of material and/or data




Possibilities on sharing samples and or data among private
entities and academic institutions
Withdraw of tissue is separated from data
Types of data bases (public/open and close) are defined
Total
NA: not applicable.as one entity (4/26) (Table 2b). Just eight samples (8/26)
discussed IRB involvement in approving the sharing of
materials or data (Table 2c). Distinctive comments in
our UAs concerning sharing material and/or data are
summarized in Table 2d.
Recontacting participants
Various circumstances can lead investigators to want to
recontact participants. The TCPS2 [10] anticipates that
if researchers collect identifiable information (Art. 5.6)
or samples (Art. 12.4) for which secondary use was ap-
proved there is no need to undergo a new consent
process. Thus, there would be no need to recontact par-
ticipants for that purpose. When the purpose of the con-
sent is to bank human biological material, researchers
are expected to determine in advance in which circum-
stances participants would be recontacted, and how
(Art. 13.7) [10].
A total of 23 (out of 37) UAs considered the possibility
of recontacting participants (Table 3a). Eight UAs (8/37)
talked about secondary use but did not mention recontact,
whereas only one (1/37) mentioned recontact without dis-
cussing future use or any particular reason for doing so.y use Total
No Not explicitly Yes
1 0 0 11
5 2 19 26
6 2 19 37
data? Total
NA No Yes
11 0 0 11
0 4 15 26






Frequency Percent Valid percent Cumulative percent
1 2.7 2.7 2.7
1 2.7 2.7 5.4
10 27.0 27.0 32.4
22 59.5 59.5 91.9
1 2.7 2.7 94.6
1 2.7 2.7 97.3
1 2.7 2.7 100.0
37 100.0 100.0
Table 3 Recontacting participants
a: Recontacting In relation of secondary use Total
NA No Yes
Recontact No 1 5 8 14
Yes 0 1 22 23
Total 1 6 30 37
b: Reasons for recontacting Frequency Percent Valid percent Cumulative percent
Valid Further health data 1 2.7 2.7 2.7
Future research 4 10.8 10.8 13.5
Future research related to present project 2 5.4 5.4 18.9
Future research, additional information 1 2.7 2.7 21.6
Future research, additional information, family members 1 2.7 2.7 24.3
Future research, family members 3 8.1 8.1 32.4
Future research, future use of biological material in genetic research 1 2.7 2.7 35.1
Future research/future information 1 2.7 2.7 37.8
Future use of samples 3 8.1 8.1 45.9
NA 14 37.8 37.8 83.8
Not specified 1 2.7 2.7 86.5
Other research projects 1 2.7 2.7 89.2
Results, recontact 3 8.1 8.1 97.3
Return results 1 2.7 2.7 100.0
Total 37 100.0 100.0
c: Recontacting_Headings Frequency Percent Valid percent Cumulative percent
Valid Do I have any options 1 2.7 2.7 2.7
Does my child have any options 1 2.7 2.7 5.4
Open consent 1 2.7 2.7 8.1
Open consent and document to recontact 1 2.7 2.7 10.8
What about confidentiality 1 2.7 2.7 13.5
Who can participate in the study 1 2.7 2.7 16.2
Confidentiality 1 2.7 2.7 18.9
Consent 7 18.9 18.9 37.8
Consent, document to recontact 2 5.4 5.4 43.2
Future contact/future research/other use 1 2.7 2.7 45.9
NA 13 35.1 35.1 81.1
Other research 1 2.7 2.7 83.8
Possibility of recontacting 1 2.7 2.7 86.5
Recruitment for future projects 1 2.7 2.7 89.2
Requirement to researcher 1 2.7 2.7 91.9
Storage and safekeeping of DNA 1 2.7 2.7 94.6
Suggested as a box 1 2.7 2.7 97.3
What about confidentiality 1 2.7 2.7 100.0
Total 37 100.0 100.0
NA: not applicable.
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ing participants in our UAs (Table 3b). Grounds for
recontacting were presented in the majority of UAs,
from participation in future studies/future research tothe return of study results – in only two UAs – and only
one referred to recontact in order to obtain additional
health information (Table 3b). The other reason for future
interaction with participants was contact and recruitment
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one UA specifies that the modality of recontacting needs
to be explained by the researcher. The matter of recon-
tacting participants was presented under vary diverse
headings (Table 3c). The role of the IRB in approving the
approach used for initiating recontact was not covered in
any of our UAs.
Secondary use, sharing material and data and
recontacting participants in genetic research studies
addressing vulnerable populations
We obtained IRB-approved consent forms for four dif-
ferent kinds of NGS studies - on mental health and
brain disorders, in adults as well as minors. The majority
of them also provided for the recruitment of non-related
healthy volunteers. Only one of the consent forms did
not discuss secondary use or recontacting participants,
and samples and data were to be used exclusively for the
issue that was prompting the study. Sharing of both ma-
terial and data was clearly explained for the purpose of
that particular research project.
The other three studies conveyed the matter of sec-
ondary use under different headings, similarly to what
we present in the general analysis. One document re-
ferred to secondary use for identical and related condi-
tions, while the rest provided participants with an array
of choices. The role of IRBs in overseeing future use was
discussed in only one document, in which participants
were also offered additional choices on secondary use.
Sharing of material and data were clearly explained as
separate entities and options for participants in this mat-
ter were present in some cases. Use of various databases
was explained. Recontacting participants was anticipated
in all three projects, so as to obtain more samples, ob-
tain more information, or for secondary use. Interest-
ingly, one anticipates secondary use in the same research
area but using a different methodology.
Request for permission to extend participation to fam-
ily members was present in all mental health and brain
disorders research projects. As for the descriptions of
genetic methodology used in these studies, one explains
briefly how a genetic marker could be detected while an-
other one states that the researchers will be using more
advanced genotyping technologies. However, none pro-
vided further details on the technical aspects of the se-
quencing procedures. We did find a more complete




There is a high percentage of UAs that mentioned the sec-
ondary use of biological material and/or data. The subject
of secondary uses was not broached in a systematic wayfrom one UA to another. We understand that these differ-
ent approaches to this subject could probably reflect indi-
vidual decisions by IRBs as to vocabulary and preferred
ways of communicating with participants. Different IRBs
conceive the ethical issues underlying secondary use dif-
ferently (e.g., confidentiality, access to samples). However,
we understand that the use of explicit terms could cer-
tainly contribute to identify the subject matter and, thus,
help participants clearly distinguish explanations about
the secondary (future) use of their genetic material and
data. Modalities on secondary uses of collected material
and information also diverged. Some UAs classified their
own options as closed, open or tiered. The majority of the
UAs discussed the secondary use of material more than
that of data. The number of UAs was insufficient for com-
parative purposes between objects of research and modal-
ities of secondary use.
Sharing what was collected (material, data, or both)
was also framed separately, like its secondary use. We
found that sharing was related most often to secondary
use, and most of the UAs referred to sharing both ma-
terial and data. Again, as to secondary use, we noted that
information on the sharing of genetic sequencing data in
a manner completely independent of the material from
which it originated was absent.
In over half of our UAs the reason to recontact a partici-
pant was to obtain consent for secondary use. In a minor-
ity of cases it was to return results or to update health
information. As NGS technologies have a high likelihood
of unveiling causative and predictive information about
clinical conditions related or unrelated to the primary goal
of a study, return of results in this context is a dominant
subject that could be perceived both as carrying a risk and
presenting a benefit to participants. We noted that not
much consideration was given to the need of recontacting
participants to update health information. Such updates
would contribute markedly to understanding new findings
in genetic research. As genetic sequencing becomes more
common in research, recruitment of participants based on
earlier genetic research results becomes of greater import-
ance. Interestingly, there wasn’t any reference to such a
possibility, although one UA reminded researchers to tell
participants if recruitment was based on genetic testing.
The role of IRBs in overseeing secondary use was clear
in the majority of the documents. However, their role was
not explicitly stated in regard to sharing samples and/or
data or on recontacting participants. We consider that the
role of the IRB should deserve equal consideration in
these three undertakings: secondary use, sharing of mater-
ial and data and recontacting participants.
The emergence of NGS technologies creates the need
for a more complex and thorough explanation of new(er)
concepts to study participants, such as sharing informa-
tion between researchers to recruiting participants based
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cance. Clarification of these issues aims to uphold the
principles of autonomy and beneficence: autonomy of re-
search participants in deciding how they want their DNA
samples (and the information derived from them) to be
handled, and beneficence in avoiding any harm due to
possible misuse of samples and data, all the while maxi-
mizing possible benefits to them, and to society as a
whole. Our content analysis of a Canadian sample of tem-
plate texts and accompanying IRB instructions addressing
the consent process for genetic studies showed compli-
ance with the requirements set forth by the TCPS2. We
found that, in Canada, there were not many gaps to bridge
between current regulations and the evolving needs re-
garding informed consent due to the increasingly wide-
spread use of NGS in relation to the three subjects
discussed in this article. There is an amount of specificity
that should be expected for any given genetic project and
that is the result of the interaction between the investiga-
tors and any IRB, and that was missing in a majority of
the documents used in our analysis. Yet, although based
on a small set, when comparing the IRB-approved con-
sent forms for brain disorders and the templates used
to prepare these documents, there were relatively few
differences.
Lastly, current literature discusses the importance of
stronger safeguards for vulnerable populations, in par-
ticular those affected by mental health or brain disor-
ders [8,9]. Cognitive limitations in individuals affected
with mental health disorders, and the likelihood of
therapeutic misconceptions in individuals with mental
health and brain disorders such as autism spectrum dis-
orders and their immediate family have been reported
and discussed [8,9,11]. However, we didn’t find any par-
ticular language addressing these participants specific-
ally in the subset of IRB-approved forms, neither in the
subjects discussed in this work nor elsewhere on the
consent forms. Mental health and brain disorders carry
additional risks of disclosure and stigma for probands
and their immediate family. It is also true that anyone
from the general population currently participating in
any type of genetic research could find out in the future
that they belong to a particularly vulnerable population.
In this respect, such individuals should be entitled to
the same protection as those entering a study with
“full” knowledge of their condition. The difference,
then, could reside in the consent process itself, which
could include more complete explanations and the re-
course to additional decision-making tools during the
consent process [16]. In any case, the correct process
for obtaining consent from any population should include
close monitoring of the informed consent process, which
means more than what the TCPS2 and present IRB forms
currently provide.Bridging the gaps with current needs
Based on the results of the present study and on
the reported impact of NGS in genetic research re-
lated to secondary use, sharing of data and material
and recontacting participants, [17-20] we deem im-
portant that the following concepts be taken into
consideration by ethics committees and researchers
so as to provide a fully informed consent to research
participants:
 In genetic studies, there must be a clear distinction
between the secondary use of biological material
and data: while DNA samples may well not be shared,
sharing of the generated genetic data can become
unavoidable [20].
 We consider that changes in technology that have
the potential to impact participants’ preferences
should be brought to their attention. Similarly to
the context of clinical trials addressed in the TCPS2
[10], when there is new information on the risk/
benefit ratio for research participants that might
modify their decision to stay in the study, this new
knowledge must be disclosed. The means of doing so
(i.e., general notifications, consent form addendums)
would greatly depend on the feasibility of any
follow-through on the part of IRBs and researchers.
 De-identified DNA is becoming more easily linked
to individuals or groups of individuals even when
using exclusively public databases [21], and DNA
could be considered a personal identifier in and of
itself [22]. Simply informing research participants
about the possibility that their genetic data might
be added to public databases, as per the TCPS2 [10],
is then no longer sufficient. When data linkage
of two or more anonymous sets of information
or human biological materials is planned, an IRB
review should be required for any population
addressed in the study, and not only for the more
vulnerable (i.e., aboriginal communities [10]). In
addition to current literature [23], we propose that
a layered consent process for genetic data sharing
would be appropriate.
 Current technological approaches to genetic studies
impact the communication between researchers
and research participants, generating further reasons
to remain in contact. To define the grounds that
promote maintaining contact with participants during
the earlier stages of a research project, we share the
position adopted by Beskow et al. on advising
participants that “recontacting will occur”, reminding
participants that the option to refuse to be informed
of the reason that prompts any recontact should
always be open [24]. All communication, as
recommended in the TCPS2 [10], should be
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Conclusions
Our analysis of Canadian consent template texts on sec-
ondary use, sharing of data and material, and recontacting
participants, in the context of genetic research, shows that
only minor, targeted modifications would be required to
increase the protection of participants in NGS research.
The ethical oversight of research projects evolves to
keep pace with ethical challenges in the face of unpredict-
able technological changes, ensuring concurrent protec-
tion of research participants. Examples of changes in
ethical oversight of research include multicenter reviews
[24], as well as current proposals to reform the ethical
management framework for low-risk, randomized re-
search projects [2]. A comparison could be drawn be-
tween these examples and the changes brought about in
the ethical management of research projects using NGS
technologies. The issues of secondary use of genetic
material or data, how the latter are shared, the need for
ongoing communication between researchers and par-
ticipants, in addition to managing, for instance, the
return of genetic results, are all common challenges to
the genetic research community at large. We thus be-
lieve that the results of our analysis could be valuable
to improve the quality of research participants’ infor-
mation and consent documentation, be it for current or
upcoming genetic studies, in Canada and elsewhere.
Competing interests
NE and BG declare no competing interests. IJG serves as a member and
consultant on ethics committees in the public and private sectors.
Authors’ contributions
IJG carried out material collection, selection and content analysis, manuscript
conception and preparation. NE participated in content analysis, contributed
to drafting the manuscript as well as its design. BG is the corresponding
author, conceived of the study and participated in its design and
coordination as well as the preparation of the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This research and the work presented in the manuscript have been
supported by a Genome Quebec grant.
Received: 19 September 2014 Accepted: 5 November 2014
Published: 20 November 2014
References
1. Hayden EC: Informed consent: a broken contract. Nature 2012,
486(7403):312–314.
2. Faden RR, Beauchamp TL, Kass NE: Informed consent, comparative
effectiveness, and learning health care. N Engl J Med 2014, 370(8):766–768.
3. Caulfield T, McGuire AL, Cho M, Buchanan JA, Burgess MM, Danilczyk U,
Diaz CM, Fryer-Edwards K, Green SK, Hodosh MA, Juengst E, Kaye J, Kedes L,
Knoppers BM, Lemmens T, Meslin EM, Murphy J, Nussbaum RL, Otlowski
M, Pullman D, Ray PN, Sugarman J, Timmons M: Research ethics
recommendations for whole-genome research: consensus statement.
PLoS Biol 2008, 6(3):e73.
4. Henderson GE: Is informed consent broken? Am J Med Sci 2011,
342(4):267–272.5. Rotimi CN, Marshall PA: Tailoring the process of informed consent in
genetic and genomic research. Genome Med 2010, 2(3):20.
6. Bredenoord AL, Onland-Moret NC, Van Delden JJ: Feedback of individual
genetic results to research participants: in favor of a qualified disclosure
policy. Hum Mutat 2011, 32(8):861–867.
7. Kronenthal C, Delaney SK, Christman MF: Broadening research consent in
the era of genome-informed medicine. Genet Med 2012, 14(4):432–436.
8. Groisman IJ, Mathieu G, Godard B: Use of next generation sequencing
technologies in research and beyond: are participants with mental
health disorders fully protected? BMC Med Ethics 2012, 13:36.
9. Mathieu G, Groisman IJ, Godard B: Next generation sequencing in
psychiatric research: what study participants need to know about
research findings. Int J Neuropsychopharmacol 2013, 16(9):2119–2127.
10. Canadian Institutes of Health Research Natural Sciences and Engineering
Research Council of Canada, & Social Sciences and Humanities Research
Council of Canada: Tri-Council Policy Statement: Ethical Conduct for
Research Involving Humans (TCPS 2). 2010, http://www.pre.ethics.gc.ca/
pdf/eng/tcps2/TCPS_2_FINAL_Web.pdf.
11. Baret L, Godard B: Opinions and intentions of parents of an autistic child
toward genetic research results: two typical profiles. Eur J Hum Genet
2011, 19(11):1127–1132.
12. Egalite N, Groisman IJ, Godard B: Genetic counseling practice in next
generation sequencing research: implications for the ethical oversight of
the informed consent process. J Genet Couns 2014, 23(4):661–670.
13. Vaismoradi M, Turunen H, Bondas T: Content analysis and thematic analysis:
implications for conducting a qualitative descriptive study. Nurs Health Sci
2013, 15(3):398–405.
14. Sparkes AC: Narrative Analysis: Exploring the Whats and Hows of Personal
Stories. In Qualitative Research in Health Care. 1st edition. Edited by Holloway I.
Berkshire: Open University Press; 2005:191–208.
15. Grbich C: Qualitative Data Analysis: An Introduction. 1st edition. London:
Sage Publications; 2007.
16. Brehaut JC, Saginur R, Elwyn G: Informed consent documentation necessary
but not sufficient. Contemp Clin Trials 2009, 30(5):388–389.
17. Kaye J, Boddington P, de Vries J, Hawkins N, Melham K: Ethical implications
of the use of whole genome methods in medical research. Eur J Hum Genet
2010, 18(4):398–403.
18. McGuire AL, Caulfield T, Cho MK: Research ethics and the challenge of
whole-genome sequencing. Nat Rev Genet 2008, 9(2):152–156.
19. Ries NM, LeGrandeur J, Caulfield T: Handling ethical, legal and social
issues in birth cohort studies involving genetic research: responses from
studies in six countries. BMC Med Ethics 2010, 11:4.
20. Tabor HK, Stock J, Brazg T, McMillin MJ, Dent KM, Yu JH, Shendure J, Bamshad MJ:
Informed consent for whole genome sequencing: a qualitative analysis of
participant expectations and perceptions of risks, benefits, and harms.
Am J Med Genet A 2012, 158A(6):1310–1319.
21. Gymrek M, McGuire AL, Golan D, Halperin E, Erlich Y: Identifying personal
genomes by surname inference. Science 2013, 339(6117):321–324.
22. Rodriguez LL, Brooks LD, Greenberg JH, Green ED: Research ethics. The
complexities of genomic identifiability. Science 2013, 339(6117):275–276.
23. McGuire AL, Oliver JM, Slashinski MJ, Graves JL, Wang T, Kelly PA, Fisher W,
Lau CC, Goss J, Okcu M, Treadwell-Deering D, Goldman AM, Noebels JL,
Hilsenbeck SG: To share or not to share: a randomized trial of consent
for data sharing in genome research. Genet Med 2011, 13(11):948–955.
24. Greene SM, Geiger AM: A review finds that multicenter studies face
substantial challenges but strategies exist to achieve Institutional Review
Board approval. J Clin Epidemiol 2006, 59(8):784–790.
doi:10.1186/1472-6939-15-80
Cite this article as: Jaitovich Groisman et al.: Consenting for current
genetic research: is Canadian practice adequate?. BMC Medical Ethics
2014 15:80.
